Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis
Identifieur interne : 005020 ( Main/Exploration ); précédent : 005019; suivant : 005021Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis
Auteurs : Julius Atashili [États-Unis, Cameroun] ; Linda Kalilani [États-Unis] ; Adaora A. Adimora [États-Unis]Source :
- BMC Infectious Diseases [ 1471-2334 ] ; 2006.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mâle, Sujet âgé, Thérapie antirétrovirale hautement active, Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique).
- MESH :
- immunologie : Grippe humaine, Infections à VIH, Vaccins antigrippaux.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Vaccins antigrippaux.
- virologie : Grippe humaine, Infections à VIH.
- Adulte, Adulte d'âge moyen, Femelle, Grippe humaine, Humains, Mâle, Sujet âgé, Thérapie antirétrovirale hautement active.
English descriptors
- KwdEn :
- Adult, Aged, Antiretroviral Therapy, Highly Active, Female, HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), Humans, Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Middle Aged.
- MESH :
- chemical , immunology : Influenza Vaccines.
- drug therapy : HIV Infections.
- immunology : HIV Infections, Influenza, Human.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- virology : HIV Infections, Influenza, Human.
- Adult, Aged, Antiretroviral Therapy, Highly Active, Female, Humans, Male, Middle Aged.
Abstract
Though influenza vaccines are the cornerstone of medical interventions aimed at protecting individuals against epidemic influenza, their effectiveness in HIV infected individuals is not certain. With the recent detection of influenza strains in countries with high HIV prevalence rates, we aimed at evaluating the current evidence on the efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals.
We used electronic databases to identify studies assessing efficacy or effectiveness of influenza vaccines in HIV patients. We included studies that compared the incidence of culture- or serologically-confirmed influenza or clinical influenza-like illness in vaccinated to unvaccinated HIV infected individuals. Characteristics of study participants were independently abstracted and the risk difference (RD), the number needed to vaccinate to prevent one case of influenza (NNV) and the vaccine effectiveness (VE) computed.
We identified six studies that assessed the incidence of influenza in vaccinated HIV-infected subjects. Four of these studies compared the incidence in vaccinated versus unvaccinated subjects. These involved a total of 646 HIV-infected subjects. In all the 4 studies, the incidence of influenza was lower in the vaccinated compared to unvaccinated subjects with RD ranging from -0.48 (95% CI: -0.63, -0.34) to -0.15 (95% CI: -0.25, 0.05); between 3 and 7 people would need to be vaccinated to prevent one case of influenza. Vaccine effectiveness ranged from 27% to 78%. A random effects model was used to obtain a summary RD of -0.27 (95%CI: -0.42, -0.11). There was no evidence of publication bias.
Current evidence, though limited, suggests that influenza vaccines are moderately effective in reducing the incidence of influenza in HIV-infected individuals. With the threat of a global influenza pandemic, there is an urgent need to evaluate the effectiveness of influenza vaccines in trials with a larger number of representative HIV-infected persons.
Url:
DOI: 10.1186/1471-2334-6-138
PubMed: 16965629
PubMed Central: 1574329
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000363
- to stream Pmc, to step Curation: 000363
- to stream Pmc, to step Checkpoint: 000E60
- to stream PubMed, to step Corpus: 001C78
- to stream PubMed, to step Curation: 001C78
- to stream PubMed, to step Checkpoint: 001B34
- to stream Ncbi, to step Merge: 000379
- to stream Ncbi, to step Curation: 000379
- to stream Ncbi, to step Checkpoint: 000379
- to stream Main, to step Merge: 005361
- to stream Main, to step Curation: 005020
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis</title><author><name sortKey="Atashili, Julius" sort="Atashili, Julius" uniqKey="Atashili J" first="Julius" last="Atashili">Julius Atashili</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, BP 8445 Yaoundé, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, BP 8445 Yaoundé</wicri:regionArea><wicri:noRegion>BP 8445 Yaoundé</wicri:noRegion></affiliation></author><author><name sortKey="Kalilani, Linda" sort="Kalilani, Linda" uniqKey="Kalilani L" first="Linda" last="Kalilani">Linda Kalilani</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Adimora, Adaora A" sort="Adimora, Adaora A" uniqKey="Adimora A" first="Adaora A" last="Adimora">Adaora A. Adimora</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="I3">School of Medicine, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16965629</idno><idno type="pmc">1574329</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574329</idno><idno type="RBID">PMC:1574329</idno><idno type="doi">10.1186/1471-2334-6-138</idno><date when="2006">2006</date><idno type="wicri:Area/Pmc/Corpus">000363</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000363</idno><idno type="wicri:Area/Pmc/Curation">000363</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000363</idno><idno type="wicri:Area/Pmc/Checkpoint">000E60</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E60</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16965629</idno><idno type="wicri:Area/PubMed/Corpus">001C78</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C78</idno><idno type="wicri:Area/PubMed/Curation">001C78</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C78</idno><idno type="wicri:Area/PubMed/Checkpoint">001B34</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B34</idno><idno type="wicri:Area/Ncbi/Merge">000379</idno><idno type="wicri:Area/Ncbi/Curation">000379</idno><idno type="wicri:Area/Ncbi/Checkpoint">000379</idno><idno type="wicri:Area/Main/Merge">005361</idno><idno type="wicri:Area/Main/Curation">005020</idno><idno type="wicri:Area/Main/Exploration">005020</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis</title><author><name sortKey="Atashili, Julius" sort="Atashili, Julius" uniqKey="Atashili J" first="Julius" last="Atashili">Julius Atashili</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="1"><nlm:aff id="I2">Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, BP 8445 Yaoundé, Cameroon</nlm:aff><country xml:lang="fr">Cameroun</country><wicri:regionArea>Center for the Study and Control of Communicable Diseases (CSCCD), Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, BP 8445 Yaoundé</wicri:regionArea><wicri:noRegion>BP 8445 Yaoundé</wicri:noRegion></affiliation></author><author><name sortKey="Kalilani, Linda" sort="Kalilani, Linda" uniqKey="Kalilani L" first="Linda" last="Kalilani">Linda Kalilani</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Adimora, Adaora A" sort="Adimora, Adaora A" uniqKey="Adimora A" first="Adaora A" last="Adimora">Adaora A. Adimora</name><affiliation wicri:level="2"><nlm:aff id="I1">Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation><affiliation wicri:level="2"><nlm:aff id="I3">School of Medicine, University of North Carolina, Chapel Hill, NC 27599–7435, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Medicine, University of North Carolina, Chapel Hill, NC 27599–7435</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author></analytic><series><title level="j">BMC Infectious Diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiretroviral Therapy, Highly Active</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Mâle</term><term>Sujet âgé</term><term>Thérapie antirétrovirale hautement active</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Infections à VIH</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiretroviral Therapy, Highly Active</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Thérapie antirétrovirale hautement active</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Though influenza vaccines are the cornerstone of medical interventions aimed at protecting individuals against epidemic influenza, their effectiveness in HIV infected individuals is not certain. With the recent detection of influenza strains in countries with high HIV prevalence rates, we aimed at evaluating the current evidence on the efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals.</p></sec><sec sec-type="methods"><title>Methods</title><p>We used electronic databases to identify studies assessing efficacy or effectiveness of influenza vaccines in HIV patients. We included studies that compared the incidence of culture- or serologically-confirmed influenza or clinical influenza-like illness in vaccinated to unvaccinated HIV infected individuals. Characteristics of study participants were independently abstracted and the risk difference (RD), the number needed to vaccinate to prevent one case of influenza (NNV) and the vaccine effectiveness (VE) computed.</p></sec><sec><title>Results</title><p>We identified six studies that assessed the incidence of influenza in vaccinated HIV-infected subjects. Four of these studies compared the incidence in vaccinated versus unvaccinated subjects. These involved a total of 646 HIV-infected subjects. In all the 4 studies, the incidence of influenza was lower in the vaccinated compared to unvaccinated subjects with RD ranging from -0.48 (95% CI: -0.63, -0.34) to -0.15 (95% CI: -0.25, 0.05); between 3 and 7 people would need to be vaccinated to prevent one case of influenza. Vaccine effectiveness ranged from 27% to 78%. A random effects model was used to obtain a summary RD of -0.27 (95%CI: -0.42, -0.11). There was no evidence of publication bias.</p></sec><sec><title>Conclusion</title><p>Current evidence, though limited, suggests that influenza vaccines are moderately effective in reducing the incidence of influenza in HIV-infected individuals. With the threat of a global influenza pandemic, there is an urgent need to evaluate the effectiveness of influenza vaccines in trials with a larger number of representative HIV-infected persons.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Cameroun</li><li>États-Unis</li></country><region><li>Caroline du Nord</li></region></list><tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Atashili, Julius" sort="Atashili, Julius" uniqKey="Atashili J" first="Julius" last="Atashili">Julius Atashili</name></region><name sortKey="Adimora, Adaora A" sort="Adimora, Adaora A" uniqKey="Adimora A" first="Adaora A" last="Adimora">Adaora A. Adimora</name><name sortKey="Adimora, Adaora A" sort="Adimora, Adaora A" uniqKey="Adimora A" first="Adaora A" last="Adimora">Adaora A. Adimora</name><name sortKey="Kalilani, Linda" sort="Kalilani, Linda" uniqKey="Kalilani L" first="Linda" last="Kalilani">Linda Kalilani</name></country><country name="Cameroun"><noRegion><name sortKey="Atashili, Julius" sort="Atashili, Julius" uniqKey="Atashili J" first="Julius" last="Atashili">Julius Atashili</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005020 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005020 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:1574329
|texte= Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16965629" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |